Ke Xu

Also affiliated with Chongqing University, Shanxi Medical University, Dalian Medical University, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Bristol-Myers Squibb (Sweden), Lanzhou City University, First Affiliated Hospital of Dalian Medical University, Shanxi Academy of Medical Sciences, First People's Hospital of Chongqing, Lanzhou University

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results”.

592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0592

N/A

0DataRank · unranked

2 citations

Richard D. Carvajal, Diwakar Davar, Eduardo Castañón, Paolo A. Ascierto, Emiliano Calvo +16 more